Loading market dashboard
Vivos Therapeutics, Inc.
VVOSHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Vivos Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript
Year-over-year revenue increased 70%, reflecting contribution from Vivos' acquisition of The Sleep Center of Nevada Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), today reported financial results and operating highlights for the first quarter ended March 31, 2026.
Some of Wall Street's biggest upside calls are not sitting in the mega-cap names. They are hiding in small, volatile stocks with thin balance sheets, limited operating history and one big event ahead.
Vivos Therapeutics (NASDAQ: VVOS) executives told investors the company's shift toward a medical provider-focused model, anchored by the June 2025 acquisition of the Sleep Center of Nevada (SCN), drove higher revenue in 2025 and is reshaping its growth strategy heading into 2026. 2025 results reflect SCN acquisition and model pivot Chief Financial Officer Bradford Amman said
Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript
Full Year 2025 revenue increased 16% Integration of The Sleep Center of Nevada and shift in business model support path to improved revenues, margins and cash flow Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), today reported financial results and operating highlights for the full year ended December 31, 2025.
LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), announced it plans to release its full year 2025 financial results after market close today, Wednesday, April 15, 2026.
Vivos Therapeutics, Inc. (NASDAQ: VVOS - Get Free Report) was the target of a large decline in short interest during the month of March. As of March 31st, there was short interest totaling 316,118 shares, a decline of 34.7% from the March 15th total of 484,373 shares. Approximately 3.1% of the shares of the stock are
LITTLETON, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), announced that it has closed on a private placement with V-Co Investors 3 LLC (“V-Co 3”), an affiliate of New Seneca Partners Inc. (“Seneca”).
Vivos Therapeutics, Inc. (NASDAQ: VVOS - Get Free Report) major shareholder Michael Skaff bought 1,353,625 shares of the company's stock in a transaction on Tuesday, March 31st. The stock was bought at an average cost of $1.34 per share, with a total value of $1,813,857.50. Following the completion of the purchase, the insider owned 1,353,625 shares
Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare
Vivos Therapeutics, Inc. (NASDAQ: VVOS - Get Free Report) shares traded up 1.5% during trading on Wednesday. The company traded as high as $1.45 and last traded at $1.34. 257,368 shares traded hands during trading, an increase of 168% from the average session volume of 95,931 shares. The stock had previously closed at $1.32. Wall
LITTLETON, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders and associated chronic health conditions, today announced that an a recent study published in the Journal of Clinical Medicine supports Vivos' long maintained belief that dental and facial morphology characterized by narrow palatal (upper) dental arches, high peaked palates, and recessed lower jaws were directly correlated to the prevalence and severity of obstructive sleep apnea (OSA) in adults and children.
